Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Beam Therapeutics (BEAM) EBITDA Margin: 2019-2025

Historic EBITDA Margin for Beam Therapeutics (BEAM) over the last 6 years, with Sep 2025 value amounting to -1,154.34%.

  • Beam Therapeutics' EBITDA Margin fell 49698.00% to -1,154.34% in Q3 2025 from the same period last year, while for Sep 2025 it was -746.15%, marking a year-over-year decrease of 70616.00%. This contributed to the annual value of -593.01% for FY2024, which is 55872.00% down from last year.
  • As of Q3 2025, Beam Therapeutics' EBITDA Margin stood at -1,154.34%, which was up 4.60% from -1,210.03% recorded in Q2 2025.
  • Beam Therapeutics' 5-year EBITDA Margin high stood at 45.99% for Q4 2023, and its period low was -3,359,583.33% during Q1 2021.
  • Over the past 3 years, Beam Therapeutics' median EBITDA Margin value was -657.36% (recorded in 2024), while the average stood at -749.55%.
  • Per our database at Business Quant, Beam Therapeutics' EBITDA Margin slumped by 284,595,000bps in 2021 and then skyrocketed by 335,873,095bps in 2022.
  • Beam Therapeutics' EBITDA Margin (Quarterly) stood at -126.84% in 2021, then slumped by 5,335bps to -180.19% in 2022, then spiked by 22,618bps to 45.99% in 2023, then plummeted by 35,009bps to -304.10% in 2024, then plummeted by 49,698bps to -1,154.34% in 2025.
  • Its EBITDA Margin was -1,154.34% in Q3 2025, compared to -1,210.03% in Q2 2025 and -1,469.73% in Q1 2025.